At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 19, 2026 at 16:05 ET
Artiva Biotherapeutics announced five data presentations at the EULAR 2026 Congress (June 3-6, 2026) for its AlloNK (AB-101) allogeneic NK cell therapy in autoimmune diseases. A late-breaking oral abstract showed 71% ACR50 response in refractory RA patients with ≥6-month follow-up, no relapses, and B-cell depletion comparable to autologous CD19 CAR T therapy. The company plans a Phase 3 registrational trial in refractory RA in 2026. This is a significant clinical data catalyst for a clinical-stage biotech, the data are early and interim but the CAR T comparability claim and refractory RA response rates are the key bullish signals.
- Five abstracts accepted at EULAR 2026, including one late-breaking oral presentation.
- Late-breaking abstract (LB0003): 71% ACR50 response in refractory RA patients with ≥6-month follow-up; zero relapses or new immunomodulatory agents required.
- First patient with severe Sjögren disease treated with AlloNK + rituximab showed positive experience (abstract OP0129).
- Data claim B-cell depletion comparable to autologous CD19 CAR T therapies (abstracts POS0355, AB0345).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access